Recent Company News

• 10:37 AM ET Apr 25, 2025
  

  EU's CHMP adopted a positive opinion recommending the granting of a marketing authorisation for Yaxwer (10870.00Ft, 0.00)

• 02:14 AM ET Apr 24, 2025
  

  Hikma Pharmaceuticals Trading Statement: Reaffirms FY guidance (1904.0000p, 0)

• 01:10 PM ET Apr 17, 2025
  

  Hikma acquires Novugen's FDA-approved ANDA for trametinib

• 11:11 AM ET Apr 17, 2025
  

  Hikma Pharmaceuticals acquires Novugen's FDA-approved ANDA for trametinib (1885.0000p, -6)

• 02:39 AM ET Apr 10, 2025
  

  Hikma Pharmaceuticals upgraded to buy from hold at Jefferies (1774.0000p, 0)

• 04:35 AM ET Apr 02, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 10:02 PM ET Apr 08, 2025
  

  Follow-up: US President Donald Trump says the US will unveil "major" tariff on imports of pharmaceutical goods - NBC News

• 05:20 AM ET Mar 25, 2025
  

  Hikma Pharmaceuticals launches Cisatracurium Besylate injection, USP, in the US (2024.0000p, +38)

• 05:26 AM ET Mar 21, 2025
  

  Shanghai Junshi Biosciences receives NMPA's additional indication approval for toripalimab in combination with bevacizumab (HK$14.50, 0.00)